Tigecycline is a glycylcycline antibiotic, first clinically available drug in a new class of antibiotics called the glycylcyclines. Tigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation. Tigecycline is given intravenously and has activity against a variety of Gram-positive and Gram-negative bacterial pathogens, many of which are resistant to existing antibiotics.

Product Active Ingredient(s) Strength Features Dosage Form
TIGENICHE Tigecycline 50 mg • Tigecycline provided clinical cure rate comparable to:
     > Combination of vancomycin aztreonam in cSSSI
     > Imipenem/cilastatin in cIAI
     > Levofloxacin in CABP
• Tigecycline had a low overall discontinuation rate due to adverse events in clinical studies
  • Complicated skin and skin structure infections (cSSSI)
  • Complicated intra-abdominal infections (cIAI)
  • Community-acquired bacterial pneumonia (CABP)
  • Tigecycline is active against many Gram-positive bacteria, Gram-negative bacteria and anaerobes – including activity against methicillin-resistant Staphylococcus aureus (MRSA), Stenotrophomonas maltophilia, Haemophilus influenzae, and Neisseria gonorrhoeae


Copyright © 2013 - Alniche Life Sciences Pvt. Ltd. | All Rights Reserved

Disclaimer: The information provided herein is not medical advice and is not intended to replace medical advice offered by a health care provider. Please consult your health care provider for advice.